A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the
safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in
patients with advanced solid tumors. The study consists of two phases: a phase 1 dose
escalation/regimen exploration phase and a phase 2 expansion phase.